Title: Clinical Study on Treament of Mild to Moderate Essential Hypertension with. Two AT_1 Antsgoist
Abstract: OBJECTS: To explore the clinical efficacy and safety of treating mild to moderate essential hypertension with valsartan and losartan. METHOD: 145 cases were assigned into two groups randomly, one was treated with valsatan 80-160mg, another with losartan 50-100mg once daily for half a.year. Causal and ambulatory blood pressure, renal and hepatic function, plasma renin activity (PRA), plasma levels of angiotensin Ⅱ(Aug Ⅱ), aldosterone(ALD) and endothelin(ET) were ditermined before and after the therapy. Cardiocerebral events were monitored. RESULTS: The total effective rate, amplitude of blood Pressure reduced, TIP ratio of systolic and diastolic blood pressure in valsartan gruop were 76.l%(56174) 26.4/15.2mmHg, 0.82 and 0.78 respectively, and those of the losartan group were 75.7%(54/71);26. 1/15.6mmHg, o.8l and 0.80 respectively.The levels of PRA and Aug n elevated after the therapy(Po.os), while those of ET decreased in both groups(P0.05), there were no significant differences between two groups (P0.05). The plasma level of uric acid also reduced after the treament in both groups(P0.05), and the higher the level before treatment,the lower the amplitude reduced. The cardiocerebral events of two groups were similar in half a year's therapy. adverse reactions in valsartan group were mild. CONCLUSION: Valsartan is a new AT_1 antagonism which is safety, and has a long and steady antihynsive effect, also shows a good tolerant profile. It is worth recommening in clinical practice.
Publication Year: 2001
Publication Date: 2001-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot